Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)

• Status: Not yet recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to demonstrate the bioequivalence between the formulation of 5 mg/mL Tramadol Hydrochloride Oral Solution (08P1902F0) Relative to the reference product Contramal® (100 mg/mL Oral Solution).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Unither Pharmaceuticals, France
• Collaborator: International Pharmaceutical Research Center
• Treatments: Pharmaceutical Solutions; Tramadol

Criteria

Inclusion Criteria:

• Male and non-pregnant female human subjects, age 18-50 years

• Body mass index between 18.5-30 Kg/m²

• Subject with normal findings

• Willingness to follow the protocol requirements

Exclusion Criteria:

• History of hypersensitivity to tramadol hydrochloride

• Significant history of asthma, thyrotoxicosis, tumours, peptic or gastric ulcer, gastrointestinal malabsorption or haemorrhage in the gastro-intestinal tract, sinusitis, pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired hepatic function), cardiovascular disorder (ex. severe heart failure), neurological disease such as epilepsy, haematological disorders or diabetes, psychiatric, dermatologic or immunological disorders

• Presence of any clinically significant results from laboratory tests,

• lactating female or woman of childbearing potential unwilling to use an effective contraception